Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Varenicline more effective for smoking cessation than bupropion
Vault Navigation
Varenicline more effective for smoking cessation than bupropion
How effective are nicotine receptor partial agonists (NRPAs) for smoking cessation?
Varenicline at standard dose (1mg twice a day) more than doubled the chances of quitting compared with placebo (NNT*11). Low-dose varenicline roughly doubled the chances of quitting, and reduced the number and severity of side effects. The most common side effect of varenicline was nausea. The number of people stopping smoking with varenicline was higher than with bupropion or with NRT (nicotine replacement therapy). Limited evidence suggested varenicline might have a role to play in relapse prevention. Cytisine was effective and affordable but absolute quit rates were modest. Dianicline was not effective and is no longer in development.
*NNT = number needed to treat to benefit 1 individual
Early reports of possible links between varenicline and suicidal ideation and behaviour have not been confirmed but concerns have been raised that it may slightly increase cardiovascular events in people already at increased risk of those illnesses.
NRPAs may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms and reducing smoking satisfaction. Varenicline is the most widely available treatment. Cytisine is a similar medication but is only available in central and eastern Europe and through internet sales.
Cahill K et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Reviews, 2016, Issue 5. Art. No.: CD006103.DOI: 10.1002/14651858. CD006103.pub7. This review contains 44 studies involving 29,353 participants.